Sharp, a leading contract development and manufacturing organization (CDMO), has announced a significant investment exceeding €20 million to bolster its European packaging infrastructure, specifically targeting the high-demand injectables market. This strategic expansion addresses the growing needs of pharmaceutical clients for advanced assembly, labelling, packaging, and cold storage solutions for formats such as autoinjectors, pen devices, pre-filled syringes, and vials.
The investment is concentrated at Sharp’s established sites in Hamont-Achel, Belgium, and Heerenveen, the Netherlands. In Belgium, the upgrades will dramatically increase capacity: cold-chain warehouse space will be quadrupled, while ambient storage will double. A new syringe assembly and blister packaging suite is being added, complemented by enhanced device assembly lines. The integration of collaborative robot technology is set to boost production efficiency on pre-filled syringe and autoinjector lines, enabling faster throughput and higher precision in operations.
In the Netherlands, the Heerenveen facility will see an expansion of GMP-compliant production areas, including two new Grade D packaging suites. These enhancements will support upcoming syringe assembly programs, vial packaging, and additional capacity to meet rising demands. Operations from these upgrades are scheduled to come online throughout 2026, positioning Sharp to handle increased volumes for new injectable drug launches across Europe.
This €20 million commitment forms part of a broader $100 million global investment strategy unveiled by Sharp in November 2025, underscoring the company’s dedication to scaling operations in response to market dynamics. The European focus reflects surging demand for specialized packaging services in the pharma sector, where injectables represent a critical growth area due to advancements in biologics, vaccines, and personalized medicines.
Robert O’Beirn, Managing Director of Sharp Clinical & Sharp Europe, emphasized the facilities’ proven track record: “Our European sites have a long-established reputation for successfully delivering the complex packaging services required for injectable drug formats.” This expertise, combined with the new investments, strengthens Sharp’s role as a reliable partner for pharmaceutical companies navigating regulatory complexities and supply chain challenges.
From a B2B perspective, this development highlights key trends in pharma packaging: the push for integrated CDMO services that encompass everything from assembly to cold-chain logistics. Suppliers and decision-makers in the sector will benefit from Sharp’s enhanced capabilities, which promise reduced lead times, improved compliance with stringent EU GMP standards, and scalable solutions for high-volume production. The adoption of robotic automation also signals a shift toward Industry 4.0 in packaging, where efficiency gains directly translate to cost savings for clients.
Market analysts note that such investments are timely amid regulatory pressures like the EU’s Packaging and Packaging Waste Regulation (PPWR), which emphasizes sustainability and recyclability. While Sharp’s focus is on primary pharma packaging, the infrastructure upgrades indirectly support greener practices through optimized material use and waste reduction in assembly processes. Partners in labelling machinery, packaging materials, and testing solutions stand to gain from these expansions, as Sharp integrates advanced equipment to maintain quality assurance.
Looking ahead, Sharp’s move reinforces Europe’s position as a hub for injectable packaging innovation. With operations ramping up in 2026, the company is poised to capture a larger share of the €612.9 billion global pharmaceutical packaging market, particularly in the primary packaging segment that dominates with 72% share. Stakeholders should monitor how this capacity increase influences contract negotiations, pricing dynamics, and collaborative opportunities in specialized packaging.
In summary, Sharp’s investment not only addresses immediate capacity constraints but also sets a benchmark for strategic growth in the packaging labelling sector, offering actionable insights for vendors, tech providers, and decision-makers eyeing partnerships in Europe’s pharma ecosystem. The blend of technological upgrades and market responsiveness exemplifies how leading players are future-proofing their operations against evolving demands.
